Fulcrum Therapeutics Inc. has provided an update on its pipeline focused on rare diseases, with a primary emphasis on the development of oral small molecules targeting benign hematological conditions. The company’s lead asset, pociredir, is positioned as a potential best-in-class oral fetal hemoglobin (HbF) inducer for sickle cell disease $(SCD)$. Pociredir has shown robust and rapid pan-cellular increases in HbF, with early evidence of improvements in hemolysis, anemia, and reduction in vaso-occlusive crises (VOCs). The drug has received Fast Track and Orphan Drug Designations, with composition of matter and method of use coverage through 2040. Recent results from the 20 mg cohort in the ongoing Phase 1b PIONEER study demonstrated a 9.9% mean absolute increase in HbF at week 6, with continued evidence of a favorable tolerability profile. An End-of-Phase meeting with the FDA is planned for the first half of 2026, and the next study is expected to initiate in the second half of 2026. As of December 31, 2025, Fulcrum reported a cash balance of $352.3 million, projecting a cash runway into 2029. The company is also advancing discovery programs focused on other benign hematological diseases. You can access the full presentation through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fulcrum Therapeutics Inc. published the original content used to generate this news brief on January 14, 2026, and is solely responsible for the information contained therein.
Comments